Lista de obras -

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

article published in 2018

1408. Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects

article by Scott A Van Wart et al published November 2018 in Open Forum Infectious Diseases

398Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures

artículo científico publicado en 2014

A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics

scientific article published on 16 January 2019

A Phase 1 Study to Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function

scholarly article by Allison S Komirenko et al published 1 October 2018 in Antimicrobial Agents and Chemotherapy

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

artículo científico publicado en 2009

Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

artículo científico publicado en 2013

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside

artículo científico publicado en 2018

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

artículo científico publicado en 2015

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window

artículo científico publicado en 2017

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue

artículo científico publicado en 2015

Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition ⬇️

artículo científico publicado el 17 de diciembre de 2010

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes

artículo científico publicado en 2016

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia

artículo científico publicado en 2009

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside

artículo científico publicado en 2017

Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection Following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multi-Center Study (ACUMIN)

artículo científico publicado en 2020

Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia

artículo científico publicado en 2013

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections

artículo científico publicado en 2014

Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

artículo científico publicado en 2009

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

artículo científico publicado en 2013

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

scientific article published on 27 April 2020

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

scientific article published on 27 March 2019

Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy

artículo científico publicado en 2021

Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections

artículo científico publicado en 2004

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia

artículo científico publicado en 2013

Population pharmacokinetics of oseltamivir: pediatrics through geriatrics

scientific article published on 13 May 2013

Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

artículo científico publicado en 2013

Population-based meta-analysis of furosemide pharmacokinetics.

artículo científico publicado en 2013

Population-based meta-analysis of hydrochlorothiazide pharmacokinetics

artículo científico publicado en 2013

Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis

artículo científico publicado en 2011

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints

artículo científico publicado en 2009

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis

artículo científico publicado en 2004

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia

artículo científico publicado en 2011

Lista de obras de

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

1408. Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects

398Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures

A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics

A Phase 1 Study to Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue

Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition ⬇️

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside

Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection Following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multi-Center Study (ACUMIN)

Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections

Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy

Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia

Population pharmacokinetics of oseltamivir: pediatrics through geriatrics

Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

Population-based meta-analysis of furosemide pharmacokinetics.

Population-based meta-analysis of hydrochlorothiazide pharmacokinetics

Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia